GlassScriptPhysician profile
Rebecca H Becherer
NPI 1194855296
$2,172.87
in general payments reported to CMS, 2019-2025
25 companies · $360 in 2025
The $360 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $207 · 2021: $450 · 2022: $356 · 2023: $302 · 2024: $312 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $271.87 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $220.43 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $214.88 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $196.50 | 2020-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Glaxosmithkline, LLC. | $179.95 | 2021-2023 | Bexsero |
| Supernus Pharmaceuticals, INC. | $153.24 | 2021-2024 | Qelbree |
| Seqirus USA INC | $149.03 | 2021-2025 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $141.44 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $113.65 | 2025 | Neffy |
| Pfizer INC. | $97.94 | 2019-2024 | |
| Genzyme Corporation | $71.56 | 2024 | |
| Sobi, INC | $68.26 | 2020-2021 | |
| Neos Therapeutics, LP | $42.74 | 2020-2022 | |
| Adlon Therapeutics L.P. | $38.91 | 2020-2021 | |
| Shire North American Group INC | $35.51 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $26.50 | 2025 | Neurostar Tms Therapy System |
| Cranial Technologies, INC | $20.67 | 2023 | Doc Band |
| Kowa Pharmaceuticals America, INC. | $18.23 | 2025 | Zoryve |
| Collegium Pharmaceutical, INC. | $17.82 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $17.44 | 2025 | Daybue |
| Ultragenyx Pharmaceutical INC. | $17.41 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $15.29 | 2023 | Flumist Quadrivalent |
| Amneal Pharmaceuticals LLC | $14.91 | 2019 | |
| Genentech USA, INC. | $14.66 | 2019 | |
| Neurelis, INC. | $14.03 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Becherer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.